Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper 2 – Gynaecological cancers

2738 - A Randomized Phase II/III Study to Assess the Efficacy of Trametinib in Patients with Recurrent or Progressive Low-Grade Serous Ovarian or Peritoneal Cancer

Date

29 Sep 2019

Session

Proffered Paper 2 – Gynaecological cancers

Presenters

David Gershenson

Citation

Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394

Authors

D.M. Gershenson1, A. Miller2, W. Brady2, J. Paul3, K. Carty3, W. Rodgers4, D. Millan5, R.L. Coleman6, K.N. Moore7, S. Banerjee8, K. Connolly9, A.A. Secord10, D.M. O'Malley11, O. Dorigo12, S. Gaillard13, H. Gabra14, P. Hanjani15, H. Huang2, L. Wenzel16, C. Gourley17

Author affiliations

  • 1 Gynecologic Oncology And Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 2 Nrg Oncology Statistics And Data Management Center, Roswell Park Comprehensive Cancer Center, 14263 - Buffalo/US
  • 3 Cancer Research Uk, Institute Of Cancer Sciences, University of Glasgow, G12 8QQ - Glasgow/GB
  • 4 Pathology, Weill Medical College of Cornell University, 11355 - New York/US
  • 5 Pathology, Queen Elizabeth University Hospital, G51 4TF - Glasgow/GB
  • 6 Gynecologic Oncology And Reproductive Medicine, The M. D. Anderson Cancer Center, 77030-3721 - Houston/US
  • 7 Obstetrics & Gynecology, Stephenson Cancer Center at the University of Oklahoma, 73104 - Oklahoma City/US
  • 8 Gynaecology Department, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 9 Medical Oncology, Edinburgh Cancer Centre, EH4 2XU - Edinburgh/GB
  • 10 Obstetrics & Gynecology, Duke University, 27710 - Durham/US
  • 11 Clinical Research Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus/US
  • 12 Obstetrics & Gynecology, Stanford University Emergency Resid, 94304 - Palo Alto/US
  • 13 Oncology And Gynecology/obstetrics, Johns Hopkins Sidney Kimmel Cancer Center, 21287 - Baltimore/US
  • 14 Surgery And Cancer, Imperial College London Hammersmith Campus, W12 0NN - London/GB
  • 15 Obstetrics & Gynecology, Abington Memorial Hospital, 19001 - Philadelphia/US
  • 16 Medicine And Public Health, University of California at Irvine, 92629 - Irvine/US
  • 17 Nicola Murray Centre For Ovarian Cancer Research, Edinburgh Cancer Research UK Centre, EH4 2XR - Edinburgh/GB
More

Resources

Login to access the resources on OncologyPRO.

Abstract 2738

Background

Low-grade serous carcinoma of the ovary/peritoneum (LGSOC) is a rare subtype, accounting for 5-10% of all serous cancers, and is characterized by alterations in the MAPK pathway, relative chemoresistance, and prolonged overall survival (OS) compared to high-grade serous carcinoma. NRG Oncology in the US and the National Cancer Research Network (NCRN) in the UK collaborated on a phase II/III trial to assess the efficacy of a MEK inhibitor trametinib (TRAM) compared to physician’s choice standard of care (SOC) in recurrent LGSOC.

Methods

Patients (pts) were randomized 1:1 to receive either TRAM 2 mg daily or 1 of 5 SOC options (weekly paclitaxel, PLD, topotecan, letrozole, or tamoxifen) until disease progression. Pts who progressed on SOC were allowed to crossover to TRAM. The primary objective tested the progression-free survival (PFS) superiority of TRAM vs SOC. Secondary objectives included toxicity, QoL, and objective response rate (ORR) by RECIST 1.1. Exploratory objectives were OS and PFS and ORR after crossover. PFS and OS curves were estimated using the Kaplan-Meier method and compared by a 1-sided, α = 0.025 log-rank test.

Results

260 pts (48.1% had >3 prior lines of therapy) were enrolled between Feb 2014 and Apr 2018. Median follow-up was 31.4 months (mo). PFS was significantly improved for TRAM compared to SOC (median, 13.0 vs 7.2 mo; HR 0.48; 95% CI, 0.36-0.64; P < .0001). ORR was 26.2% for TRAM vs 6.2% for SOC (OR 5.4; 95% CI, 2.39-12.21; P< .0001). Response duration for TRAM was significantly better than for SOC (median, 13.63 mo; 95% CI, 8.08-18.76; vs 5.88 mo; 95% CI, 2.76-12.19). Preliminary analysis of QoL patient reported outcomes shows no significant therapy effects. Main Grade >3 AE in TRAM vs SOC were hematologic toxicity (13.4% vs 9.4%), GI toxicity (27.6% vs 29%), skin toxicity (15% vs 3.9%), and vascular toxicity (18.9% vs 8.6%). Median OS for TRAM vs SOC was 37.0 mo (95% CI, 30.3-NE) vs 29.2 mo (95% CI, 23.5-51.6) (HR 0.75; 95% CI, 0.51-1.11). For 88 pts who crossed over to TRAM, median PFS = 10.8 mo (95% CI, 7.3-12.0), and ORR = 15% (95% CI, 0.07-0.22).

Conclusions

Compared to physician’s choice SOC, TRAM was associated with significantly improved PFS and ORR in women with recurrent LGSOC.

Clinical trial identification

NCT02101788.

Editorial acknowledgement

Legal entity responsible for the study

National Cancer Institute (NRG Oncology).

Funding

National Cancer Institute (US) and Novartis.

Disclosure

W. Brady: Full / Part-time employment: Sarah Cannon Development Innovations. R.L. Coleman: Advisory / Consultancy, Leadership role, Research grant / Funding (self), Non-remunerated activity/ies: AbbVie; Honoraria (self), Advisory / Consultancy: aravive; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Non-remunerated activity/ies: AstraZeneca; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: clovis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Roche Genentech; Honoraria (self), Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Novartisjavascript:%20create_table_line(’1’,%20new%20Array(’ent’,%20’des’,%20’tor’));; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Janssen; Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Merck; Honoraria (self), Advisory / Consultancy, Non-remunerated activity/ies: Immunogen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro/GSK; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Genmab; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Gamamab; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Oncomed; Honoraria (self), Advisory / Consultancy: Agenus; Research grant / Funding (self), Research grant / Funding (institution): NCI-SPORE. K.N. Moore: Honoraria (institution), Advisory / Consultancy: Clovis. S. Banerjee: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Tesaro; Honoraria (self): Clovis; Honoraria (self): Merck Sereno; Honoraria (self): Seattle Genetics; Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self): PharmaMar; Research grant / Funding (institution): Janssen Cilag; Honoraria (self), Travel / Accommodation / Expenses: Gamamabs. A.A. Secord: Research grant / Funding (institution): AbbVie, Amgen, Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Eisai, Endocyte, Exelixis, Incyte, Merck, PharmaMar, Immutep Ltd, Roche/Genentech, Seattle Genetics, Inc, TapImmune and Tesaro; Honoraria (self): Aravive, AstraZeneca, Clovis, Janssen/Johnson & Johnson, Merck, Mersana, Oncoquest, Roche/Genentech, and Tesaro . D.M. O’Malley: Honoraria (self), Advisory Board: Genelux; Honoraria (self), Research grant / Funding (institution), Advisory Board: Eisai; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): GOG Foundation; Honoraria (self): NCCN; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Immunogen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Advisory board, Steering Committee: Clovis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Advisory board: Abbie, Iovance ; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), US PI/Steering Committee: Novocure; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Advisory board, Steering Committee: Tesaro; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Advisory board, steering Committee: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Advisory board, PI, Steering Committee: Agenus; Honoraria (self), Advisory / Consultancy, Advisory board: OncoQuest; Honoraria (self), Advisory / Consultancy, Advisory board: Ambry; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): AMGEN, BMS; Research grant / Funding (institution): Array Biopharma, inVentiv ; Research grant / Funding (institution): Janssen, Tracon; Research grant / Funding (institution): EMD Serono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Advisory board: Leap Therapeutics. O. Dorigo: Advisory / Consultancy, Speaker Bureau / Expert testimony: Tesaro; Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Clovis; Advisory / Consultancy: Merck. S. Gaillard: Research grant / Funding (institution): Pfizer, Bristol-Myers Squibb, Genentech/Roche, Gradalis, Iovance Biotherapeutics, Merck, PharmaMar, TetraLogic Pharmaceuticals, AbbVie; Advisory / Consultancy: AstraZeneca, Immunogen. C. Gourley: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Honoraria (institution), Advisory / Consultancy: Roche; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Tesaro; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Nucana; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Clovis; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Foundation One; Honoraria (self), Honoraria (institution), Advisory / Consultancy: Sierra Oncology; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Cor2ED; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Aprea. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings